These insights—along with a deeper mechanistic understanding of the long-term adaptations to GYS1 knockdown and induced sensitivity to mitochondrial inhibitors—will help to select breast tumors that are most susceptible to therapeutic targeting of glycogen metabolism. The gene discussed is GYS1; the disease is breast neoplasm.